Q-omics provides the consensus-scored FAIM2 profile across patient tissues and cancer cell-line models. FAIM2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAIM2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FAIM2 RNA expression shows 17,498 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where FAIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAIM2 survival associations across molecular data types. FAIM2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAIM2 RNA expression–survival associations across cancer types. High FAIM2 expression shows unfavorable associations in BLCA and KIRC, but favorable associations in HNSC, UCEC, LGG and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAIM2 RNA expression.
This table summarizes FAIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAIM2 shows lower tumor expression in BLCA, HNSC, KIRC, KIRP, KICH and STAD. The BLCA box plot shows higher FAIM2 RNA expression in normal versus tumor tissue (log2 FC = −3.287, t-test p < 0.001).
This table shows molecular features associated with FAIM2 in patient tissues and cancer cell lines. In patient samples, FAIM2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
